Skip to content
Screener

Beam Therapeutics BEAM Total Liabilities & Equity

Total Liabilities & Equity at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$27.42B+14.1%
Arrowhead Research logo
Arrowhead ResearchARWR
$2.27B+44.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.26B-3.2%
MGN
MagniteMGNI
$3.03B+3.6%
Wave Life Sciences logo
Wave Life SciencesWVE
$558.32M+121%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$857.16M-4.6%

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$2.81B+52.0%
Enterprise value$2.78B+61.1%
P/S17.2×-13.6×

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:22 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210338
Line itemMarch 31,2026December 31,2025
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.01 par value; 250,000,000 shares authorized, 102,741,848 and 101,748,962 issued and outstanding at March 31, 2026 and December 31, 2025, respectively1,0271,017
Additional paid-in capital2,900,0182,877,449
Accumulated other comprehensive (loss) income(1,070)1,111
Accumulated deficit(1,735,537)(1,641,219)
Total stockholders’ equity1,164,4381,238,358
Total liabilities and stockholders’ equity$1,480,798$1,481,177

Item 1. Financial Statements (Unaudited)

FAQ

What is Beam Therapeutics's total liabilities & equity?
Beam Therapeutics (BEAM) reported total liabilities & equity of $1.48B in Q1 2026.
How has Beam Therapeutics's total liabilities & equity changed year-over-year?
Beam Therapeutics's total liabilities & equity increased by 0.9% year-over-year, from $1.47B to $1.48B.
What is the long-term trend for Beam Therapeutics's total liabilities & equity?
Over 5 years (2020 to 2025), Beam Therapeutics's total liabilities & equity has grown at a 26.8% compound annual growth rate (CAGR), from $451.68M to $1.48B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Beam Therapeutics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude